1. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future

   • Małgorzata Łobocka
   • Krystyna Dąbrowska
   • Andrzej Górski

   Leading Article Open access 21 April 2021 Pages: 255 - 280

   

2. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success

   • Salvatore Fiorenza
   • Cameron J. Turtle

   Review Article 07 April 2021 Pages: 281 - 302

   

3. Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

   • Hannah J. Yu
   • Charles C. Wykoff

   Review Article 24 April 2021 Pages: 303 - 323

   

4. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study

   • Irene Marafini
   • Carmine Stolfi
   • Giovanni Monteleone

   Original Research Article Open access 19 April 2021 Pages: 325 - 336

   

5. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

   • Binghe Xu
   • Qingyuan Zhang
   • HLX02-BC01 Investigators

   Original Research Article Open access 07 April 2021 Pages: 337 - 350

   

6. Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators

   • Louise C. Druedahl
   • Sofia Kälvemark Sporrong
   • Anna Birna Almarsdóttir

   Original Research Article 08 April 2021 Pages: 351 - 361

7. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey

   • Allison R. Kolbe
   • Aaron Kearsley
   • Amber Jessup

   Original Research Article 07 April 2021 Pages: 363 - 372

   

8. Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”

   • Joerg Putzke
   • Scott Haughie
   • Gopinath M. Ranganna

   Letter to the Editor Open access 16 April 2021 Pages: 373 - 374

9. Author’s Reply to Joerg Putzke et al. Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”

   • Jingjing Qian
   • Cong Bang Truong
   • Kaniz Afroz Tanni

   Letter to the Editor 16 April 2021 Pages: 375 - 377